Boundless Bio (BOLD) Cash from Investing Activities (2023 - 2026)

Boundless Bio (BOLD) has reported Cash from Investing Activities for 4 consecutive years, with $14.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 376.7% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $49.3 million (up 219.79% YoY), while the FY2025 annual figure was $37.8 million, up 244.83% from the prior year.
• Cash from Investing Activities grew to $14.6 million in Q1 2026 per BOLD's latest filing, from $13.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $22.2 million in Q1 2023 and bottomed at -$68.5 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$921000.0 across 4 years, with a median of $11.3 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 88.47% — and 2025, when it surged 611.52%.
• Boundless Bio's Cash from Investing Activities stood at $15.8 million in 2023, then tumbled by 88.47% to $1.8 million in 2024, then soared by 611.52% to $13.0 million in 2025, then rose by 12.46% to $14.6 million in 2026.
• Business Quant data shows BOLD's Cash from Investing Activities at $14.6 million in Q1 2026, $13.0 million in Q4 2025, and $10.5 million in Q3 2025.